The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Industry s Direct’s proprietary databases, Firms ’s corporate website, SEC filings, investor presentations and featured press releases, both from industry player and market -specific third party sources, put together by Global Industry s Direct’s team.

Scope of the Research

- Fondazione Neoplasie Sangue Onlus - Brief industry player overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Fondazione Neoplasie Sangue Onlus human therapeutic division.
- Detailed Analysis of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Fondazione Neoplasie Sangue Onlus with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Fondazione Neoplasie Sangue Onlus’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Why Should You Get This Report?

- Evaluate Fondazione Neoplasie Sangue Onlus’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Fondazione Neoplasie Sangue Onlus in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Fondazione Neoplasie Sangue Onlus’s Research and Development portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Fondazione Neoplasie Sangue Onlus.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Fondazione Neoplasie Sangue Onlus and identify potential opportunities in those areas.

Table Of Contents

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Fondazione Neoplasie Sangue Onlus Snapshot 5
Key Information 5
Key Facts 5
Fondazione Neoplasie Sangue Onlus - Research and Development Overview 6
Key Therapeutic Areas 6
Fondazione Neoplasie Sangue Onlus - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Combination Treatment Modalities 11
Fondazione Neoplasie Sangue Onlus - Pipeline Products Glance 12
Fondazione Neoplasie Sangue Onlus - Late Stage Pipeline 12
Phase III Products/Combination Treatment Modalities 12
Fondazione Neoplasie Sangue Onlus Clinical Stage Pipeline Products 13
Phase II Products/Combination Treatment Modalities 13
Fondazione Neoplasie Sangue Onlus - Drug Profiles 14
Bortezomib + Melphalan + Prednisone + Thalidomide 14
Product Description 14
Mechanism of Action 14
RandD Progress 15
Cyclophosphamide + Lenalidomide + Dexamethasone 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
Cyclophosphamide + Prednisone + Lenalidomide 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
Melphalan + Prednisone + Lenalidomide 19
Product Description 19
Mechanism of Action 19
RandD Progress 19
Melphalan + Stem Cell Transplantation 20
Product Description 20
Mechanism of Action 20
RandD Progress 20
Velcade + Melphalan + Thalidomide + Prednisone 21
Product Description 21
Mechanism of Action 21
RandD Progress 21
Velcade + Prednisone + Melphalan 23
Product Description 23
Mechanism of Action 23
RandD Progress 23
Dasatinib + Melphalan + Prednisone 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
Dasatinib + Melphalan + Prednisone 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
Everolimus 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
Pomalidomide + Cyclophosphamide + Prednisone 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
Fondazione Neoplasie Sangue Onlus - Pipeline Analysis 29
Fondazione Neoplasie Sangue Onlus - Pipeline Products by Therapeutic Class 29
Fondazione Neoplasie Sangue Onlus Pipeline Products By Target 31
Fondazione Neoplasie Sangue Onlus - Pipeline Products by Route of Administration 33
Fondazione Neoplasie Sangue Onlus - Pipeline Products by Molecule Type 34
Fondazione Neoplasie Sangue Onlus - Locations And Subsidiaries 35
Head Office 35
Appendix 36
Methodology 36
Coverage 36
Secondary Research 36
Primary Research 36
Expert Panel Validation 37
Contact Us 37
Disclaimer 37List of Tables
Fondazione Neoplasie Sangue Onlus - Pipeline by Therapy Area and Indication, 2010 7
Fondazione Neoplasie Sangue Onlus - Pipeline by Stage of Development, 2010 9
Fondazione Neoplasie Sangue Onlus - Monotherapy Products in Pipeline, 2010 10
Fondazione Neoplasie Sangue Onlus - Combination Treatment Modalities in Pipeline, 2010 11
Fondazione Neoplasie Sangue Onlus - Phase III, 2010 12
Fondazione Neoplasie Sangue Onlus - Phase II, 2010 13
Fondazione Neoplasie Sangue Onlus - Pipeline By Therapeutic Class, 2010 29
Fondazione Neoplasie Sangue Onlus - Pipeline By Target, 2010 31
Fondazione Neoplasie Sangue Onlus - Pipeline By Route of Administration, 2010 33
Fondazione Neoplasie Sangue Onlus - Pipeline By Molecule Type, 2010 34

List of Figures
Fondazione Neoplasie Sangue Onlus - Pipeline by Therapy Area and Indication, 2010 7
Fondazione Neoplasie Sangue Onlus - Pipeline by Stage of Development, 2010 9
Fondazione Neoplasie Sangue Onlus - Monotherapy Products in Pipeline, 2010 10
Fondazione Neoplasie Sangue Onlus - Combination Treatment Modalities in Pipeline, 2010 11
Fondazione Neoplasie Sangue Onlus - Pipeline By Therapeutic Class, 2010 29
Fondazione Neoplasie Sangue Onlus - Pipeline By Target, 2010 31
Fondazione Neoplasie Sangue Onlus - Pipeline By Route of Administration, 2010 33
Fondazione Neoplasie Sangue Onlus - Pipeline By Molecule Type, 2010 34

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

Chronic Lymphocytic Leukaemia: KOL Insight

Chronic Lymphocytic Leukaemia: KOL Insight

  • $ 5 369
  • Industry report
  • May 2014
  • by Firstword Pharma

Chronic lymphocytic leukaemia (CLL) is the most common of the leukaemias, but until recently it has been underserved in terms of effective therapeutic options. However, a revolution in personalised and ...

ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations

ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations

  • $ 4 995
  • Industry report
  • July 2014
  • by GBI Research

ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations Summary GBI Research has released the pharma report, “ADHD Therapeutics ...

Inhaled COPD Therapeutics Market

Inhaled COPD Therapeutics Market

  • $ 3 850
  • Industry report
  • June 2014
  • by Greystone Research Associates

COPD is not one but a family of conditions, each with its own etiology and treatment challenges. Chronic bronchitis is the inflammation and eventual scarring of the lining of the bronchial tubes. Oral ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.